PharmiWeb.com - Global Pharma News & Resources
24-Oct-2018

Cyclica’s Cloud-Based Platform, Ligand Express, Will Help New Discovery Efforts in Bioactive Products for the National Research Council (NRC) of Canada

Cyclica is pleased to announce that, through the Build in Canada Innovation Program (BCIP), a team of scientists from the National Research Council of Canada (NRC) will have access to Ligand Express—Cyclica’s cloud-based platform.

Accessing Ligand Express will help advance new discovery efforts at the NRC, particularly in naturally occurring bioactive products. This new technology will provide important insights to enhance how the NRC's Aquatic and Crop Resource Development Research Centre conduct target identification and off-target profiling in compound discovery.

Naheed Kurji, President and CEO of Cyclica said, “It’s an honour to have a large team of scientists from the National Research Council access our platform over an extended period of time to support their R&D efforts. This is a great opportunity to further demonstrate the value of Ligand Express for not only traditional pharmaceutical drug discovery, but to natural products as well. Gaining feedback from expert scientists at the NRC will also enhance the design and functionality of Ligand Express going forward, which important for us as we are constantly looking to build elegant and friendly products that are valued and appreciated by the end user.”

About Cyclica:

Cyclica is a Toronto-based biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalize medicines. To learn more, visit www.cyclicarx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005644/en/

Editor Details

  • Company:
    • Business Wire
  • Website:
Last Updated: 24-Oct-2018